Long-Term Follow-Up of P-BCMA-101 for Multiple Myeloma
Trial Summary
What is the purpose of this trial?
Subjects are enrolled in this study following completion or early discontinuation from a Poseida sponsored or supported study of P-BCMA-101 T cells and will be followed for a total of 15 years post treatment from the last P-BCMA-101 treatment. Subjects will be monitored for safety and efficacy to assess the risk of delayed adverse events (AEs) and assess long-term efficacy, and PK and quantification of P-BCMA-101 T cells. Rimiducid may be administered as indicated.
Do I need to stop my current medications for this trial?
The trial protocol does not specify whether you need to stop taking your current medications, so it's unclear. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment P-BCMA-101 for Multiple Myeloma?
Is P-BCMA-101 safe for humans?
How is the treatment P-BCMA-101 different from other treatments for multiple myeloma?
P-BCMA-101 is a novel treatment that targets B-cell maturation antigen (BCMA), which is highly expressed in multiple myeloma cells. This approach is part of a new wave of immunotherapies that aim to improve patient outcomes by specifically targeting cancer cells and modifying the immune environment, offering a unique mechanism compared to traditional therapies.13101112
Research Team
Rajesh Belani, M.D.
Principal Investigator
Sponsor Executive Medical Director
Eligibility Criteria
This trial is for individuals who have previously received P-BCMA-101 T cell treatment for multiple myeloma, either completing or discontinuing early from a Poseida sponsored study. Participants must consent to long-term follow-up.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive P-BCMA-101 T cells treatment
Follow-up
Participants are monitored for safety and efficacy to assess the risk of delayed adverse events and long-term efficacy
Open-label extension
Participants may receive Rimiducid as indicated and are monitored for long-term safety and efficacy
Treatment Details
Interventions
- P-BCMA-101
- Rimiducid
Find a Clinic Near You
Who Is Running the Clinical Trial?
Poseida Therapeutics, Inc.
Lead Sponsor
California Institute for Regenerative Medicine (CIRM)
Collaborator